MDL Congestion Grows Even as Cases Depart

Products Liability (PL) MDLs FY 2018 vs. FY 2017¹



- In FY 2017, PL MDL cases made up 89% of cases in MDLs and 42% of the federal civil caseload.²
- In FY 2018, PL MDL cases made up 91% of cases in MDLs and 47% of the federal civil caseload.3

Top PL MDL Arrivals ⁴		Top PL MDL Departures ⁵	
Johnson & Johnson Talcum Powder	+8,433	Ethicon, Inc., Pelvic Repair System	- 7,974
Taxotere (Docetaxel)	+7,888	Fresenius GranuFlo/NaturaLyte Dialysate	– 958
Boston Scientific Corp. Pelvic Repair System	+5,653	Stryker Rejuvenate and ABG II Hip Implant	- 594
Xarelto (Rivaroxaban)	+4,187	Propecia (Finasteride)	– 541
Proton-Pump Inhibitor (No. II)	+2,135	Yasmin and Yaz (Drospirenone)	- 449

Growing congestion in MDLs adds urgency to the need for changes to the Federal Rules of Civil Procedure.

Sources

¹ http://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-FY-2017.pdf; https://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-FY-2018.pdf

² Based on Duke Law Center methodology. Civil cases include all cases minus Social Security and prisoner cases, except death penalty cases. https://www.uscourts.gov/sites/default/files/data_tables/jb_c3a_0930.2017.pdf; http://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-FY-2017.pdf

³ Based on Duke Law Center methodology. Civil cases include all cases minus Social Security and prisoner cases, except death penalty cases. https://www.uscourts.gov/sites/default/files/data_tables/jb_c3a_0930.2018.pdf; http://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-FY-2018.pdf

⁴ http://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-FY-2017.pdf

⁵ http://www.jpml.uscourts.gov/sites/jpml/files/JPML_Statistical_Analysis_of_Multidistrict_Litigation-FY-2018.pdf